10-Q: Protagenic Therapeutics Reports Increased Q1 Loss Amidst Ongoing Clinical Trials

Protagenic Therapeutics experienced a significant increase in operating losses during the first quarter of 2024, primarily due to increased research and development expenses.

Summary

• Protagenic Therapeutics reported a net loss of $1,724,294 for the first quarter of 2024, compared to a net loss of $718,096 for the same period in 2023.
• The company's operating loss increased to $1,738,359 in Q1 2024 from $739,294 in Q1 2023, driven by a substantial rise in research and development expenses.
• Research and development expenses surged to $1,460,746 in Q1 2024, up from $348,031 in Q1 2023, while general and administrative expenses decreased to $277,613 from $391,263.
• As of March 31, 2024, Protagenic had cash reserves of $831,778 and working capital of $2,021,702.
• The company anticipates needing additional debt or equity financing by the third quarter of 2024 to continue operations.
• There is substantial doubt about the company's ability to continue as a going concern due to insufficient resources to fund operations beyond the third quarter of 2024.
• The company's Phase I/IIa clinical trial for PT00114 commenced on September 26, 2023, and is evaluating the drug's potential in treating neuropsychiatric conditions.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a going concern issue, and material weaknesses in internal controls, which are major negative indicators for investors. While the company is progressing with clinical trials, the financial instability overshadows the positive aspects.

Positives

• The company has commenced its Phase I/IIa clinical trial for PT00114, a key milestone in its drug development program.
• Protagenic has exclusive worldwide rights to PT00114 through its license agreement with the University of Toronto.
• The company has completed preclinical experiments required for IND filing.
• The company has a novel mechanism of action for its lead compound, PT00114.
• The company has a positive working capital of $2,021,702 as of March 31, 2024.

Negatives

• The company experienced a significant increase in net loss and operating loss in Q1 2024 compared to Q1 2023.
• The company's cash reserves are insufficient to fund operations beyond the third quarter of 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has a history of recurring losses and negative cash flows from operations.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash reserves.
• The company is dependent on securing additional debt or equity financing by the third quarter of 2024.
• The company has material weaknesses in its internal control over financial reporting.
• The company is subject to risks and uncertainties related to its research and development activities, clinical trials, and regulatory approvals.
• The company may not be able to successfully commercialize its product candidates.
• The company's expenses may fluctuate significantly from quarter to quarter and year to year.

Future Outlook

The company anticipates further losses in the development of its business and will need to obtain debt or equity financing by the third quarter of 2024 to continue operations. There is substantial doubt about the company's ability to continue as a going concern.

Management Comments

• Management believes that the credit risk with regard to cash deposits is not significant.
• Management has determined its subsidiary's local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.
• Management intends to implement controls and procedures to address the material weakness in internal control over financial reporting.

Industry Context

The company is operating in the biopharmaceutical industry, which is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company's focus on neuropsychiatric disorders aligns with a growing need for new treatments in this area.

Comparison to Industry Standards

• Protagenic's increased R&D spending is typical for a development-stage biotech company, but the magnitude of the increase is significant.
• The company's cash burn rate is high, and the need for additional financing by Q3 2024 is a concern.
• Many comparable companies in the biotech sector are also facing challenges in securing funding and managing cash flow.
• The company's reliance on a single lead compound, PT00114, is a risk factor, as is typical for early-stage biotech companies.
• The company's Phase I/IIa trial is a key milestone, but the outcome is uncertain, as is typical for early-stage clinical trials.
• Companies like Agenus Inc., which is a related party, are also involved in research and development, but their financial situations and product pipelines may differ significantly.

Related Party Transactions

• The company is provided free office space by the Company Executive Chairman, Dr. Armen.
• The company incurred $0 in expenses related to research and development services from Agenus Inc. during the three months ended March 31, 2024.
• The company incurred $0 in expenses related to research and development services from CTC North, GmbH during the three months ended March 31, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issue.
• Employees may be concerned about the company's ability to continue operations and their job security.
• Customers and suppliers may be hesitant to engage with the company due to its financial challenges.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to secure additional debt or equity financing by the third quarter of 2024.
• The company will continue its Phase I/IIa clinical trial for PT00114.
• The company will address the material weaknesses in its internal control over financial reporting.
• The company will continue to answer regulatory questions in the US and Germany.

Key Dates

Keywords

biopharmaceutical, neuropsychiatric disorders, clinical trials, PT00114, research and development, financial results, going concern, internal control, stress-related disorders, TCAP